Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Immunotherapy and lung cytopathology: Overview and possibilities
View through CrossRef
AbstractImmunotherapy has become a promising cancer treatment in the past decade, and IHC is the most commonly used testing method for PDL‐1/PD1 evaluation. In general, PD‐L1 assays can be performed on both FFPE specimens and cytological samples. However, their use on smears is not yet well‐established or validated. Nowadays, digital images and advanced algorithms can aid in interpreting PD‐L1 in cytological samples. Understanding the immune environment of non‐small cell lung cancer (NSCLC) is critical in developing successful anticancer immunotherapies. The use of a multiplexed immunofluorescence (mIF) assay on cytological samples obtained through minimally invasive methods appears to be a viable option for investigating the immune environment of NSCLC. This review aims to briefly summarize the knowledge of the role of cytopathology in the analysis of PD‐L1 by immunocytochemistry (ICC) and future directions of cytopathology in the immunotherapy setting.
Title: Immunotherapy and lung cytopathology: Overview and possibilities
Description:
AbstractImmunotherapy has become a promising cancer treatment in the past decade, and IHC is the most commonly used testing method for PDL‐1/PD1 evaluation.
In general, PD‐L1 assays can be performed on both FFPE specimens and cytological samples.
However, their use on smears is not yet well‐established or validated.
Nowadays, digital images and advanced algorithms can aid in interpreting PD‐L1 in cytological samples.
Understanding the immune environment of non‐small cell lung cancer (NSCLC) is critical in developing successful anticancer immunotherapies.
The use of a multiplexed immunofluorescence (mIF) assay on cytological samples obtained through minimally invasive methods appears to be a viable option for investigating the immune environment of NSCLC.
This review aims to briefly summarize the knowledge of the role of cytopathology in the analysis of PD‐L1 by immunocytochemistry (ICC) and future directions of cytopathology in the immunotherapy setting.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Time to Start Up: CT-Basted Radiomics in Children’s Lung Diseases
Time to Start Up: CT-Basted Radiomics in Children’s Lung Diseases
Radiomics is a new interdisciplinary field and a fusion product consisting by large data technology and medical image to aid diagnosis. Radiomics can gather information from differ...
Blunt Chest Trauma and Chylothorax: A Systematic Review
Blunt Chest Trauma and Chylothorax: A Systematic Review
Abstract
Introduction: Although traumatic chylothorax is predominantly associated with penetrating injuries, instances following blunt trauma, as a rare and challenging condition, ...
Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
Abstract
Objective
It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 upta...
Abstract 1345: Evidence for genetic mediation of lung cancer through hay fever.
Abstract 1345: Evidence for genetic mediation of lung cancer through hay fever.
Abstract
Introduction: In the past decade, advances in genetics have led to the discovery of numerous lung cancer susceptibility variants. The majority of these vari...
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Objectives:
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non–small cell lung cancer (NSCLC).
...
Correlation between tumor mutation burden and response to immunotherapy.
Correlation between tumor mutation burden and response to immunotherapy.
e14579 Background: The use of immunotherapy is exponentially increasing in treatment of patients with advanced solid tumors. However, the response rates vary significantly between...
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Lung cancer is the second most common cancer with a poor survival rate (18.6%). Recently treatment of lung cancer has been improved starting from choosing appropriate treatment by ...